

Cabotegravir 600mg prolonged-release suspension for injection (Vocabria®)

SMC Drug ID	Conditions	Decision	Date or Expected Date of Decision
SMC2376	In combination with rilpivirine prolonged-release injection, for the treatment of Human Immunodeficiency Virus type 1 (HIV-1) infection in adults who are virologically suppressed (HIV-1 RNA <50 copies/mL) on a stable antiretroviral regimen without present or past evidence of viral resistance to, and no prior virological failure with agents of the NNRTI and INI class.	Not routinely available as the ADTC is waiting for further advice from local clinical experts – decision expected by	31/01/2022

Web Links <https://www.scottishmedicines.org.uk/medicines-advice/cabotegravir-vocabria-full-smc2376/>

Other Decision Specified

Date of ADTC 20/10/2021

Olaparib 100mg and 150mg film-coated tablets (Lynparza®)

SMC Drug ID	Conditions	Decision	Date or Expected Date of Decision
SMC2366	As monotherapy for the treatment of adult patients with metastatic castration-resistant prostate cancer and BRCA1/2-mutations (germline and/or somatic) who have progressed following prior therapy that included a new hormonal agent.	Available in line with local or regional guidance	15/12/2021

Web Links <https://www.scottishmedicines.org.uk/medicines-advice/olaparib-lynparza-full-smc2366/>

Other Decision Specified

Date of ADTC 20/10/2021

Cabozantinib 20mg, 40mg and 60mg film-coated tablets (Cabometyx®)

SMC Drug ID	Conditions	Decision	Date or Expected Date of Decision
SMC2386	In combination with nivolumab for the first-line treatment of advanced renal cell carcinoma in adults.	Not routinely available as the ADTC is waiting for further advice from local clinical experts – decision expected by	31/01/2022

Web Links <https://www.scottishmedicines.org.uk/medicines-advice/cabozantinib-cabometyx-abb-smc2386/>

Other Decision Specified

Date of ADTC 20/10/2021

Empagliflozin 10mg film-coated tablets (Jardiance®)

SMC Drug ID	Conditions	Decision	Date or Expected Date of Decision
SMC2396	In adults for the treatment of symptomatic chronic heart failure with reduced ejection fraction.	Available in line with local or regional guidance	19/01/2022

Web Links <https://www.scottishmedicines.org.uk/medicines-advice/empagliflozin-jardiance-abb-smc2396/>

Other Decision Specified

Date of ADTC 20/10/2021

Liraglutide 6mg/mL solution for injection in pre-filled pen (Saxenda®)

SMC Drug ID	Conditions	Decision	Date or Expected Date of Decision
SMC2378	<p>As an adjunct to a reduced-calorie diet and increased physical activity for weight management in adult patients with an initial Body Mass Index (BMI) of:</p> <ul style="list-style-type: none"> • $\geq 30\text{kg/m}^2$ (obese), or • $\geq 27\text{kg/m}^2$ to $< 30\text{kg/m}^2$ (overweight) in the presence of at least one weight-related comorbidity such as dysglycaemia (prediabetes or type 2 diabetes mellitus), hypertension, dyslipidaemia or obstructive sleep apnoea. 	Not routinely available as not recommended for use in NHS Scotland	20/10/2021

Web Links <https://www.scottishmedicines.org.uk/medicines-advice/liraglutide-saxenda-full-smc2378/>

Other Decision Specified

Date of ADTC 20/10/2021

Bempedoic acid / ezetimibe 180mg / 10mg film-coated tablets (Nustendi®)

SMC Drug ID	Conditions	Decision	Date or Expected Date of Decision
SMC2406	<p>In adults with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia, as an adjunct to diet:</p> <ul style="list-style-type: none"> * in combination with a statin in patients unable to reach LDL-C goals with the maximum tolerated dose of a statin in addition to ezetimibe, * alone in patients who are either statin-intolerant or for whom a statin is contraindicated, and are unable to reach LDL-C goals with ezetimibe alone * in patients already being treated with the combination of bempedoic acid and ezetimibe as separate tablets with or without statin. <p>SMC restriction: for use in patients who are:</p> <ul style="list-style-type: none"> * statin intolerant or for whom a statin is contra-indicated and * where ezetimibe alone does not appropriately control LDL-C and * where proprotein convertase subtilisin/ kexin type 9 (PCSK9) inhibitors are not appropriate. 	Available in line with local or regional guidance	20/04/2022

Web Links <https://www.scottishmedicines.org.uk/medicines-advice/bempedoic-acidezetimibe-nustendi-abb-smc2406/>

Other Decision Specified

Date of ADTC 20/10/2021

Vericiguat 2.5mg, 5mg and 10mg film-coated tablets (Verquvo®)

SMC Drug ID	Conditions	Decision	Date or Expected Date of Decision
SMC2425	Treatment of symptomatic chronic heart failure in adult patients with reduced ejection fraction who are stabilised after a recent decompensation event requiring IV therapy.	Not routinely available as not recommended for use in NHS Scotland	20/10/2021

Web Links <https://www.scottishmedicines.org.uk/medicines-advice/vericiguat-verquvo-non-sub-smc2425/>

Other Decision Specified

Date of ADTC 20/10/2021

Isatuximab 20mg/mL concentrate for solution for infusion (Sarclisa®)

SMC Drug ID	Conditions	Decision	Date or Expected Date of Decision
SMC2423	In combination with carfilzomib and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.	Not routinely available as not recommended for use in NHS Scotland	20/10/2021

Web Links <https://www.scottishmedicines.org.uk/medicines-advice/isatuximab-sarclisa-non-sub-smc2423/>

Other Decision Specified

Date of ADTC 20/10/2021

Midazolam 2mg/mL oral solution in single-dose container (Ozalin®)

SMC Drug ID	Conditions	Decision	Date or Expected Date of Decision
SMC2392	In children from 6 months to 17 years old, for moderate sedation before a therapeutic or diagnostic procedure or as premedication before anaesthesia.	Not routinely available as there is a local preference for alternative medicines	17/11/2021

Web Links <https://www.scottishmedicines.org.uk/medicines-advice/midazolam-ozalin-abb-smc2392/>

Other Decision Specified

Date of ADTC 20/10/2021

Avapritinib 100mg, 200mg and 300mg film-coated tablets (Ayvakyt®)

SMC Drug ID	Conditions	Decision	Date or Expected Date of Decision
SMC2424	As monotherapy for the treatment of adult patients with unresectable or metastatic gastrointestinal stromal tumours (GIST) harbouring the platelet-derived growth factor receptor alpha (PDGFRA) D842V mutation.	Not routinely available as not recommended for use in NHS Scotland	20/10/2021

Web Links <https://www.scottishmedicines.org.uk/medicines-advice/avapritinib-ayvakyt-non-sub-smc2424/>

Other Decision Specified

Date of ADTC 20/10/2021

Chlorprocaine hydrochloride 10mg/mL solution for injection (Ampres®)

SMC Drug ID	Conditions	Decision	Date or Expected Date of Decision
SMC2373	Spinal anaesthesia in adults where the planned surgical procedure should not exceed 40 minutes. SMC restriction: for use in day-case anaesthetic pathways.	Available in line with local or regional guidance	15/12/2021

Web Links <https://www.scottishmedicines.org.uk/medicines-advice/chlorprocaine-hydrochloride-ampres-resub-smc2373/>

Other Decision Specified

Date of ADTC 20/10/2021
